Name :
Human BCMA Protein, ECD (Extracellular Domain), Fc-fusion, Recombinant
Description :
BCMA (B cell maturation antigen), is a single-pass, type III transmembrane glycoprotein in the TNF receptor superfamily (TNFRSF17). BCMA contains a short extracellular domain (ECD) of 84 amino acid (aa), containing one TNFR cysteine-rich repeat. Within the TNFRSF, it shares the highest homology with TACI (TNFRSF13B). Both BCMA and TACI have been shown to bind to APRIL (TNFSF13) and BAFF (TNFSF13B), members of the TNF ligand superfamily. BCMA is expressed in immune organs and mature B cells, but not in T-cells or monocytes. BCMA is located on the cell surface and also found in a perinulear Golgi-like structure. The binding of BCMA to APRIL or BAFF has been shown to stimulate IgM production in peripheral blood B cells and increase the survival of B cells, suggesting that BCMA may play an important role in B cell development, function and regulation. BCMA lacks a death domain (DD) in the cystoplasmic region. BCMA interacts with various TNFR-associated factors (TRAFs), including TRAF1, TRAF2 and TRAF3, to transduce signals for B cell survival and proliferation. Overexpression of BCMA activates NF-κB and JNK signaling pathways. A chromosomal aberration in BCMA is found in a form of T-cell acute lymphoblastic leukemia (T-ALL).
Gene Symbol :
TNFRSF17; CD269; BCM; TNFRSF13A
NCBI Gene ID :
608
Uniprot Entry :
Q02223
Construct Details :
The recombinant human BCMA-Fc fusion is expressed as a 281 amino acid protein consisting of Leu2 – Ala54 region of BCMA (UniProt accession #Q02223) and a C-terminal Fc from human IgG1, which exists as a dimer under non-reducing conditions (see the gel image inserted above).
Source :
Human cells stably expressing human BCMA-Fc and growing in chemical-defined media with no animal components or antibiotics
Amino Acid Sequence: :
10 20 30 40 50 60 LQMAGQCSQN EYFDSLLHAC IPCQLRCSSN TPPLTCQRYC NASVTNSVKG TNASTGTHTC 70 80 90 100 110 120 PPCPAPELLG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN 130 140 150 160 170 180 AKTKPREEQY NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 190 200 210 220 230 240 QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL 250 260 270 280 YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
M.W. :
Calculated molecular mass (kDa): 31.3; Estimated by SDS-PAGE under reducing condition (kDa): ~45
Calculated PI :
7.63
Calculated Extinction Coefficients :
(M-1 cm-1, at 280nm): 39140
Endotoxin Level :
>95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as “DTT: +”)
Formulation :
Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier & preservative free).
Endotoxin Level :
<0.1 EU per 1 μg of purified recombinant protein determined by the LAL method
Biological Activity :
Binds to its ligand APRIL and BAFF. Inhibits APRIL- and BAFF-mediated signaling activities including NF-κB activation and proliferation of anti-IgM co-stimulated B cells.
Molecule Class :
1-Pass Type III Transmembrane
Gene Synonym :
<0.1 EU per 1 μg of purified recombinant protein determined by the LAL method
Gene Family :
BCMA; TNFRSF17; CD269; BCM; TNFRSF13A
Research Area :
Immunology
Pathway/Disease :
B Cell Development
Species :
Human
CD Antigen :
CD269
References :
1. J Immunol. 165:1322 (2000). 2. Immunol Res.26: 323 (2002). 3. J. Exp. Med. 192:129 (2000). 4. Nature 404:995 (2000). 5. Nat. Immunol. 1:252 (2000).
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
BUP-1 Protein
XG/Xg blood group Protein
Popular categories:
Mitogen-Activated Protein Kinase 12 (p38 gamma/MAPK12)
MMP-16
